Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7527.092 | 0.9585 | 0.9588 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7527.092 | 0.9730 | 0.9734 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7527.092 | 0.9630 | 0.9633 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7527.092 | 0.9724 | 0.9727 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7527.092 | 0.9832 | 0.9835 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7527.092 | 0.9817 | 0.9819 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7527.092 | 0.6418 | 0.6089 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7527.092 | 0.0163 | -0.7345 | 2.0383 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7527.092 | 0.0080 | -0.8133 | 2.0383 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7528.091 | 0.9462 | 0.8859 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7528.091 | 1.0322 | 1.0684 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7528.091 | 0.9973 | 0.9944 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7528.091 | 1.0367 | 1.0779 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7528.091 | 1.0635 | 1.1350 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7528.091 | 1.0164 | 1.0349 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7528.091 | 0.8056 | 0.5899 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7528.091 | 0.0295 | -0.9526 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7528.091 | 0.0055 | -0.9921 | 0.9421 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7529.09 | 1.0206 | 1.0918 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7529.09 | 0.9909 | 0.9602 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7529.09 | 0.9933 | 0.9705 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7529.09 | 1.0349 | 1.1569 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7529.09 | 1.0399 | 1.1803 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7529.09 | 0.9665 | 0.8553 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7529.09 | 0.9557 | 0.8098 | 0.4538 |